NCT07258836

A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

A Phase 1, Open-Label Study to Evaluate the Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

Conditions

• Neoplasms
• Healthy

Interventions

Type	Name	Description
DRUG	LY4214835	Administered IV

Timeline

• Start date: 2025-12-22
• Primary completion: 2027-01-01
• Completion: 2027-01-01
• First posted: 2025-12-02
• Last updated: 2026-04-17

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study